Zoetis Inc. (ZTS): what the price assumes

boothcheck covers Zoetis Inc. (ZTS) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-08-07.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/ZTS

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7.6% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: n/a

Valuation X-Ray

The price is supported by asset-based and relative-multiple and growth-DCF value, while earnings-power lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset, Relative, Growth Families that call it expensive: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.3%); the inversion above states its own rate.

Per-Model Detail (n=16)

Solvency

Bullet Takeaways

• Two thirds of this company is pets and one third is farm animals, and in the June 2026 quarter the two moved in opposite directions: United States companion animal sales fell 11% while United States livestock sales rose 23%, and the international business grew 6% on an organic operational basis.

• The risk is no longer hypothetical, because management has already conceded it: on August 6, 2026 Zoetis revised its full-year plan to organic operational revenue of negative 3% to negative 1% and adjusted net income growth of negative 9% to negative 5%, citing lower clinic visits and pet owner price sensitivity.

• What to watch: two long-acting monoclonal antibody pain treatments, Lenivia and Portela, have launched in Canada and the European Union and were approved in Great Britain, and a new chief financial and operating officer takes the seat on August 17, 2026.

Bull Case

The trajectory here has split in two, and the half that is working is the half nobody paid for. In the June 2026 quarter, sales of livestock products in the United States rose 23%, supported by strength across cattle and poultry, while companion animal sales in the same market fell 11%. The international business grew 6% on an organic operational basis, with its parasiticide range and its diagnostics business both contributing. A company reporting flat revenue is usually a company where nothing is happening. Here two large things are happening and they are cancelling.

Livestock is the steadier of the two by construction, and the annual filing explains why in a single line: because these products exist to improve a producer's economics rather than to satisfy a preference, demand for our products has historically been more stable than demand for other production inputs. Farmers do not defer a vaccination the way a household defers a check-up. That stability was on display in the June quarter in an unwelcome form. With New World screwworm now confirmed in the United States, Zoetis holds Dectomax-CA1, the first parasite control product to receive conditional approval from the Food and Drug Administration for prevention and treatment of screwworm myiasis in beef cattle, and received an emergency use authorization covering swine, sheep, deer, horses and dairy cattle. In July the European Commission granted marketing authorization for Poulvac Procerta HVT-ND, a poultry vaccine against Newcastle and Marek's disease.

The underlying profitability has not gone anywhere either. Over the first half of 2026 the business turned 4,730 million dollars of revenue into 1,722 million dollars of profit before interest and tax, against 1,779 million on 4,672 million a year earlier. Cost of sales ran 28.2% of revenue across 2025, improved from 29.4% the year before on price increases and a portfolio divestiture. This is a business with the cost structure of a branded pharmaceutical company and the collection risk of a cash retailer, since as the filing notes the business is primarily self-pay and the products are often directly prescribed and dispensed by veterinarians.

Management is behaving as though it agrees the shares are mispriced. Shares outstanding fell from 424.9 million at the end of 2025 to 414.2 million by June 30, 2026, with the cost of treasury stock rising 1,160 million dollars over the same six months, and the quarterly dividend was lifted to 53.0 cents from 50.0 cents. Retiring 2.5% of the share count in half a year is a real transfer to the holders who stay.

The pipeline is the part that determines whether the current stumble is a pause or a plateau. The company describes more than 12 potential blockbuster candidates in development across chronic kidney disease, oncology, cardiology, anxiety and obesity, and states a commitment to deliver a significant approval in a major market every year for the next several years. Against that, the two osteoarthritis antibodies now launching outside the United States give a concrete near-term read on whether the innovation engine still converts. Lenivia and Portela deliver up to three months of pain relief from a single injection, which is a different product from a monthly dose, and international companion animal revenue grew while the same category shrank at home.

Bear Case

Something changed in the household, not in the laboratory. For years the animal health thesis rested on an observation about behaviour: people treat pets as family and do not economize on family. The June 2026 quarter says that is no longer reliably true. Management named the cause directly, pointing to lower clinic visits and pet owner price sensitivity across parts of the portfolio. The annual filing had already flagged the same mechanism, warning that economic pressure may cause some pet owners to forgo or defer visits to veterinary practices or reduce their willingness to treat pet health conditions or even to continue to own a pet, and that customers may seek lower price alternatives to our products. The risk factor came true.

The damage is concentrated in the franchises that defined the company. United States companion animal sales fell 11% in the quarter, with the dermatology range and Simparica Trio hit by both price sensitivity and heightened competition, generic entrants pressuring the Cerenia and Convenia brands, and lower sales of Librela. That is not one product disappointing. It is the premium end, the parasiticide end and the newest launch, all softening together in the same market.

Generic erosion is structural and the company has a template for how it goes. The 10-K names the precedent plainly: Draxxin currently competes with generic products in key markets including the U.S., Europe, Canada, Mexico and Australia, and adds that we continue to face increased competition from generic products and lower cost alternatives. Each expiry converts a priced product into a commodity one, and the schedule of expiries does not pause when demand softens.

Then the guidance, which is the part that removes the argument about interpretation. On August 6, 2026 the company revised its full-year outlook to organic operational revenue of negative 3% to negative 1% and adjusted net income growth of negative 9% to negative 5%, with adjusted diluted earnings per share of 6.15 to 6.25 dollars. A shrinking top line at a company whose fixed cost base was built for growth is how operating profit falls faster than sales.

Which is exactly the arithmetic today's quote is exposed to. The price already assumes the business goes backwards; it sits below what this profit stream would be worth even if operating profit declined roughly 5% a year indefinitely. That sounds like a cushion, and it is one. It is only a cushion, though, if the decline stops somewhere near that pace. The current guidance is inside that band and the pipeline may well close it. But the same low multiple that makes the shares look defended is what the market pays when it believes a franchise is eroding rather than pausing, and nothing in the June quarter distinguishes the two.

The buying power on the other side of the trade is consolidating, too. The filing warns that there has been a trend towards the concentration of veterinarians in large clinics and hospitals and that consolidation of customers and distributors could negatively affect the pricing of our products. Price growth of roughly 4% carried most of the company's 2025 revenue gain. If the clinics negotiate as groups while pet owners shop on cost, the lever that has been doing the work gets shorter from both ends.

Finally, the funding of the capital return deserves a look. Long-term debt stood at 9,048 million dollars at June 30, 2026, essentially unchanged over six months, while the company spent 1,160 million dollars on its own shares and let liquid balances fall from 2,450 million dollars at the end of 2025 to 1,476 million. Buying stock is the right call if the shares are cheap. It is an expensive call if earnings are still on the way down.

Valuation

Start with the shape of the bet, which is unusual for a company of this quality: the quote does not require growth. It sits below what this stream of profit would justify even if operating profit shrank on the order of 5% a year from here. That is a bound rather than a forecast, and it is worth stating as one. It says the market has already priced a business in retreat, which means the question for a buyer is not whether Zoetis grows but whether the retreat is orderly.

Three of the four reference checks available have usable comparisons behind them, and there is no read at all on how often a decline of that pace persists once it starts. Read the label as directional, then. What the references do say is that the assumption is broadly consistent with plausible outcomes, and that against its own cohort the multiple sits in the lower half of the peer range rather than at either extreme.

The profit being valued needs its basis named, because Zoetis does not publish an operating income line. Its income statement runs cost of sales, selling and administrative expense, research, amortization, restructuring and then interest expense straight through to a pre-tax subtotal. Strip the interest back out and the operating result for 2025 was 3,546 million dollars on revenue of 9,467 million. The first half of 2026 produced 1,722 million dollars on 4,730 million, against 1,779 million a year earlier. Flat revenue, slightly lower profit, and the decline concentrated in the higher-priced half of the portfolio.

The methods used to triangulate this company do something they rarely do, which is to bracket the quote rather than sit on one side of it. The asset-value approaches and the peer-multiple approaches both land at or a little above where the shares trade. The forward cash-flow approaches land close by. Only the earnings-power approaches, which capitalize today's profit stream at a required return and credit no growth whatsoever, put the price about 50% above their central estimate. Read together that is a value-supported profile rather than a growth bet, and it is the mirror image of what this company's valuation looked like when it was compounding.

Cohort position sharpens rather than softens the picture. IDXX grew trailing revenue 13.1% and holds a 31.6% operating margin; PAHC grew 26.0%; ELAN grew 10.5%. Zoetis is the largest of them and currently the slowest, which is why it is also the cheapest. Whether that is an opportunity or an accurate assessment depends entirely on the companion animal line, and the June quarter did not settle it.

On the balance sheet the picture is plain: 9,048 million dollars of long-term borrowings at June 30, 2026, with no current maturities on the face of the balance sheet, against liquid balances of 1,476 million dollars that fell over the half year as 1,160 million dollars went into repurchasing stock. The obligations are long-dated and the interest bill is small relative to the profit stream. Nothing about the capital structure forces a decision. That is precisely why the argument here is about the durability of the companion animal franchise and about nothing else.

Catalysts

The June-quarter report and a guidance revision arrived together on August 6, 2026. Revenue was 2,468 million dollars, flat against the prior-year quarter and down 1% on an organic operational basis, with net income of 691 million dollars and diluted earnings per share of 1.65 dollars. The full-year outlook came down to organic operational revenue of negative 3% to negative 1%, adjusted net income growth of negative 9% to negative 5%, and adjusted diluted earnings per share of 6.15 to 6.25 dollars.

The same day brought a change in the finance seat. James Saccaro was appointed executive vice president, chief financial officer and chief operating officer effective August 17, 2026, arriving from the equivalent role at GE HealthCare and, before that, at Baxter International; the mandate as filed covers capital allocation and financial strategy plus oversight of global manufacturing and supply. A finance chief who also owns manufacturing is a specific choice, and it points at where the company thinks its next margin is.

Two product threads are live and both are datable. Lenivia and Portela, the long-acting osteoarthritis antibodies, launched in Canada and the European Union, were approved in Great Britain, and Lenivia was also approved in Switzerland; their uptake is the cleanest available test of whether the companion animal weakness is a market condition or a competitive one. Separately, the confirmed arrival of New World screwworm in the United States has put Dectomax-CA1 and Dectomax into active use under a conditional approval and an emergency use authorization, which is near-term livestock revenue that was not in anyone's plan at the start of the year.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• ELAN (Elanco Animal Health Incorporated)
• FY2025 10-K: …potentially increasing their market share and pricing power, which could lead to a decrease in our revenue and profitability. For example, many of our competitors have relationships with key distributors and, because of their size, an ability to offer attractive pricing incentives, which may negatively impact or…
• FY2025 10-K: …distribution channels outside of the veterinary clinic to sell our pet health products. If we or our major retail customers are not successful in navigating the shifting consumer preferences to distribution channels such as e-commerce, our expected future revenues may be negatively impacted. We may also realize lower…
• PAHC (Phibro Animal Health Corporation)
• FY2025 10-K: Latin America and increased domestic demand for swine products. Mineral Nutrition Net sales of $253.2 million for the year ended June 30, 2025 increased $9.6 million, or 4%, primarily due to an increase in demand for copper and trace minerals. 70 Table of Contents Performance Products Net sales of $80.2 million for…
• FY2025 10-K: …(and potential broader military conflict in the region). ​ 39 Table of Contents We have manufacturing facilities located in Brazil and a portion of our sales and earnings is attributable to products produced and operations conducted in Brazil. Our Brazilian manufacturing facilities and local operations accounted for…
• IDXX (IDEXX LABORATORIES INC /DE)
• FY2025 10-K: …our competition, refer to "Part I, Item 1A. Risk Factors." Competitive factors in our different business areas are detailed below: • Companion animal diagnostic offerings . We compete primarily on the basis of ease of use and speed of our products, diagnostic accuracy, product quality, breadth of our product line and…
• FY2025 10-K: …operator of corporate hospital chains that also sells veterinary point-of-care diagnostic instruments. Consolidation among our competitors and our customers may intensify the competition we face. While we believe that our offerings are competitively differentiated due to our innovative products and services that…
• AMRX (AMNEAL PHARMACEUTICALS, INC.)
• FY2025 10-K: …those products. We face intense competition in the pharmaceutical industry from both brand and generic drug product companies, which could significantly limit our growth and materially adversely affect our financial results. The pharmaceutical industry is highly competitive. The principal competitive factors in the…
• FY2025 10-K: …of the corresponding branded drug product to be sold during any period of marketing exclusivity that is awarded, which reduces gross margins during the marketing exclusivity period. Branded drug product companies may also reduce the price of their branded drug product to compete directly with generic drug products…
• TEVA (TEVA PHARMACEUTICAL INDUSTRIES LIMITED)
• FY2025 10-K: …and customer service. The biosimilars business is also highly competitive and continues to evolve as intellectual property protections for biological products continue to expire in the United States. While we believe that our biologics knowledge and experience provide us with competitive advantages, we anticipate…
• FY2025 10-K: …of our net sales from our major customers, see note 19 to our consolidated financial statements. Our revenues and profits from generic products may decline as a result of competition from other pharmaceutical companies and changes in regulatory policy. Our generic products face intense competition. Prices of generic…
• OGN (Organon & Co.)
• FY2025 10-K: …to make such pivot effectively, or a failure to develop and maintain a presence in China or emerging markets could adversely affect our business, cash flow, results of operations, financial condition or prospects. We face intense competition from competitors' products. Our products face intense competition from…
• FY2025 10-K: …rights are increasingly being challenged by competitors and the outcome can be highly uncertain. An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge…
• VTRS (Viatris Inc)
• FY2025 10-K: …We take very seriously our continued and comprehensive oversight of our entire manufacturing network. Patient safety remains our primary and unwavering focus. We will work closely with our customers to mitigate any possible supply disruptions and meet the needs of the patients we serve. For additional information,…
• FY2025 10-K: …encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. Certain Market and Industry Factors The global pharmaceutical industry is a highly competitive and…
• BHC (Bausch Health Companies Inc.)
• FY2025 10-K: …in trade, social media and medical periodicals, exhibit products at medical conventions and sponsor medical education symposia. 10 Competition Competitive Landscape for Products and Products in Development The pharmaceutical and medical device industries are highly competitive. Our competitors include specialty and…
• FY2025 10-K: …making such forward-looking statements, including, but not limited to, factors and assumptions relating to: (i) our ability to execute our business strategy, business plans and operational efficiency initiatives; (ii) demand for, competitive positioning of and pricing for our current and anticipated products and our…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.